Ko Hanai1, Tetsuya Babazono2, Yasuko Uchigata1. 1. Diabetes Center, Tokyo Women's Medical University School of Medicine, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan. 2. Diabetes Center, Tokyo Women's Medical University School of Medicine, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan. babazono@dmc.twmu.ac.jp.
Abstract
BACKGROUND: Effects of statins on kidneys in diabetic patients remain unclear. METHODS: This was an observational, historical cohort study of type 2 diabetic patients with estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2. We studied 412 patients newly prescribed statins, and 946 controls without a prescription history of statins (including the follow-up period). Outcomes were annual change in eGFR, ≥30 % decrease in eGFR from baseline, and progression of albuminuria, analyzed using a propensity score matching. RESULTS: A total of 168 pairs were matched for propensity score. Annual eGFR change (mL/min/1.73 m2/year) in the statin group was greater than in controls (-2.24 vs. -1.56, p = 0.024). The hazard ratio of the statin group (vs. controls) for ≥30 % decrease in eGFR and progression of albuminuria was 1.74 (p = 0.082) and 0.85 (p = 0.624), respectively. When the statin group was classified by differences in statin solubility, eGFR change and hazard ratio for ≥30 % decrease in eGFR in the lipophilic statin group were greater than in controls (-2.64 vs. -1.71, p = 0.031 and 2.15, p = 0.049); however, the outcomes in the hydrophilic statin group were not different (-2.35 vs. -1.71, p = 0.106 and 1.08, p = 0.827). The hazard ratio of lipophilic and hydrophilic statin group (vs. controls) for progression of albuminuria was 1.31 (p = 0.552) and 0.69 (p = 0.367). In the analyses using the unmatched cohort, similar results were obtained. CONCLUSIONS: Statins have no beneficial effects on kidneys in diabetic patients. In fact, lipophilic statins might have potential harmful effects on kidney function.
BACKGROUND: Effects of statins on kidneys in diabeticpatients remain unclear. METHODS: This was an observational, historical cohort study of type 2 diabeticpatients with estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2. We studied 412 patients newly prescribed statins, and 946 controls without a prescription history of statins (including the follow-up period). Outcomes were annual change in eGFR, ≥30 % decrease in eGFR from baseline, and progression of albuminuria, analyzed using a propensity score matching. RESULTS: A total of 168 pairs were matched for propensity score. Annual eGFR change (mL/min/1.73 m2/year) in the statin group was greater than in controls (-2.24 vs. -1.56, p = 0.024). The hazard ratio of the statin group (vs. controls) for ≥30 % decrease in eGFR and progression of albuminuria was 1.74 (p = 0.082) and 0.85 (p = 0.624), respectively. When the statin group was classified by differences in statin solubility, eGFR change and hazard ratio for ≥30 % decrease in eGFR in the lipophilic statin group were greater than in controls (-2.64 vs. -1.71, p = 0.031 and 2.15, p = 0.049); however, the outcomes in the hydrophilic statin group were not different (-2.35 vs. -1.71, p = 0.106 and 1.08, p = 0.827). The hazard ratio of lipophilic and hydrophilic statin group (vs. controls) for progression of albuminuria was 1.31 (p = 0.552) and 0.69 (p = 0.367). In the analyses using the unmatched cohort, similar results were obtained. CONCLUSIONS: Statins have no beneficial effects on kidneys in diabeticpatients. In fact, lipophilic statins might have potential harmful effects on kidney function.
Authors: Saswata Deb; Peter C Austin; Jack V Tu; Dennis T Ko; C David Mazer; Alex Kiss; Stephen E Fremes Journal: Can J Cardiol Date: 2015-05-23 Impact factor: 5.223
Authors: Dick de Zeeuw; Deborah A Anzalone; Valerie A Cain; Michael D Cressman; Hiddo J Lambers Heerspink; Bruce A Molitoris; John T Monyak; Hans-Henrik Parving; Giuseppe Remuzzi; James R Sowers; Donald G Vidt Journal: Lancet Diabetes Endocrinol Date: 2015-02-04 Impact factor: 32.069
Authors: M Friederich Persson; S Franzén; S-B Catrina; G Dallner; P Hansell; K Brismar; F Palm Journal: Diabetologia Date: 2012-02-05 Impact factor: 10.122
Authors: Tushar Acharya; Jian Huang; Steven Tringali; Christopher R Frei; Eric M Mortensen; Ishak A Mansi Journal: Am J Cardiol Date: 2015-12-02 Impact factor: 2.778
Authors: Helen M Colhoun; D John Betteridge; Paul N Durrington; Graham A Hitman; H Andrew W Neil; Shona J Livingstone; Valentine Charlton-Menys; David A DeMicco; John H Fuller Journal: Am J Kidney Dis Date: 2009-06-21 Impact factor: 8.860
Authors: Richard Haynes; David Lewis; Jonathan Emberson; Christina Reith; Lawrence Agodoa; Alan Cass; Jonathan C Craig; Dick de Zeeuw; Bo Feldt-Rasmussen; Bengt Fellström; Adeera Levin; David C Wheeler; Rob Walker; William G Herrington; Colin Baigent; Martin J Landray Journal: J Am Soc Nephrol Date: 2014-05-01 Impact factor: 10.121
Authors: Clarissa J Diamantidis; Hayden B Bosworth; Megan M Oakes; Clemontina A Davenport; Jane F Pendergast; Sejal Patel; Jivan Moaddeb; Huiman X Barnhart; Peter D Merrill; Khaula Baloch; Matthew J Crowley; Uptal D Patel Journal: Contemp Clin Trials Date: 2018-04-10 Impact factor: 2.226